文献速递糖尿病肥胖与代谢综合征

GLP-1受体激动剂是否增加乳腺癌风险?系统综述与荟萃分析

Do GLP-1 Receptor Agonists Increase the Risk of Breast Cancer? A Systematic Review and Meta-analysis.
PubMed 文献 · J Clin Endocrinol Metab · 2021-01-01

该系统综述与荟萃分析纳入52项随机对照试验,评估GLP-1受体激动剂(GLP-1RA)治疗肥胖和/或糖尿病是否增加乳腺肿瘤风险。结果显示,GLP-1RA组与对照组乳腺癌风险无显著差异(RR 0.98,95%CI 0.76-1.26),良性乳腺肿瘤风险亦无差异(RR 0.99,95%CI 0.48-2.01)。结论认为GLP-1RA不增加乳腺癌风险。

要点

  • GLP-1RA治疗不增加乳腺癌风险(RR 0.98,95%CI 0.76-1.26)。
  • 良性乳腺肿瘤风险亦无显著差异(RR 0.99,95%CI 0.48-2.01)。
  • 亚组分析(随访时间、盲法、药物类型)未见差异。

核心结论

  • GLP-1RA用于肥胖和糖尿病治疗不增加乳腺肿瘤风险。

研究设计与样本

  • 系统综述与荟萃分析,检索MEDLINE、Embase、Web of Science和CENTRAL(2019年7月31日至2020年2月8日)。
  • 纳入52项随机对照试验,受试者为超重/肥胖和/或糖尿病成人,随访至少24周。
  • 50项试验报告乳腺癌事件,11项报告良性乳腺肿瘤;采用RoB 2.0评估偏倚风险,GRADE评估证据质量。

主要发现

  • 良性乳腺肿瘤风险组间无差异(RR 0.99,95%CI 0.48-2.01)。
  • 按随访时间、参与者/研究者盲法及GLP-1RA类型进行的亚组分析未显示差异。
  • 试验序贯分析提示样本量足以避免遗漏替代结果。

临床怎么用

  • 对于肥胖或糖尿病患者,使用GLP-1RA时无需因乳腺癌风险担忧而限制其应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Risk of cancer is a major concern in the development of drugs for the treatment of obesity and diabetes. In randomized controlled trials (RCTs) of the Liraglutide Clinical Development Program, subjects treated with a glucagon-like peptide-1 receptor agonist (GLP-1RA) had a higher absolute number of breast cancer events. OBJECTIVE: To assess whether patients treated with GLP-1RAs had a higher risk of breast neoplasms. DATA SOURCES: We searched MEDLINE, Embase, Web of Science, and CENTRAL from July 31, 2019 to February 8, 2020. STUDY SELECTION: Reviewers assessed abstracts and full-text articles for RCTs of GLP-1RAs in adults with excessive weight and/or diabetes and a minimum follow-up of 24 weeks. DATA EXTRACTION: Researchers extracted study-level data and assessed within-study risk of bias with the RoB 2.0 tool and quality of evidence with Grading of Recommendations Assessment, Development and Evaluation (GRADE). DATA SYNTHESIS: We included 52 trials, of which 50 reported breast cancer events and 11 reported benign breast neoplasms. Overall methodological quality was high. Among 48 267 subjects treated with GLP-1RAs, 130 developed breast cancer compared with 107 of 40 755 controls (relative risk [RR], 0.98; 95% confidence interval [CI], 0.76-1.26). Subset analyses according to follow-up, participant/investigator blinding, and type of GLP-1RA did not reveal any differences. The risk of benign breast neoplasms also did not differ between groups (RR, 0.99; 95% CI, 0.48-2.01). Trial sequential analysis provided evidence that the sample size was sufficient to avoid missing alternative results. CONCLUSIONS: Treatment with GLP-1RAs for obesity and diabetes does not increase the risk of breast neoplasms.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Piccoli GF, Mesquita LA, Stein C, et al. Do GLP-1 Receptor Agonists Increase the Risk of Breast Cancer? A Systematic Review and Meta-analysis. J Clin Endocrinol Metab. 2021. PMID: 33248445. doi:10.1210/clinem/dgaa891

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。